GlassScriptPhysician profile
Todd Campbell
NPI 1821603465
$4,801.44
in general payments reported to CMS, 2019-2025
34 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2023: $272 · 2024: $2,321 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,608 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,608.49 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $558.33 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $538.05 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $495.41 | 2024-2025 | Korlym |
| Medtronic, INC. | $438.40 | 2024-2025 | Minimed 780g |
| Amgen INC. | $397.98 | 2024-2025 | Evenity, Repatha, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.81 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $248.89 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $134.13 | 2024-2025 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $132.31 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $130.11 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Chiesi USA, INC. | $120.18 | 2024 | Mycapssa, Juxtapid |
| Novo Nordisk INC | $117.36 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $116.12 | 2023-2025 | Tymlos |
| Abbvie INC. | $107.40 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $94.31 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $91.56 | 2024-2025 | Evkeeza |
| Ascendis Pharma Endocrinology INC | $80.74 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $75.19 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $67.75 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $45.59 | 2024-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $37.09 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Amneal Pharmaceuticals LLC | $36.90 | 2024-2025 | Unithroid |
| Abbott Laboratories | $28.77 | 2025 | Freestyle Libre 3 |
| Vifor Pharma, INC. | $26.12 | 2023 | Veltassa |
| Amphastar Pharmaceuticals, INC. | $25.81 | 2024 | Baqsimi |
| Kyowa Kirin, INC. | $23.18 | 2024 | Crysvita |
| Beta Bionics, INC. | $19.65 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Averitas Pharma INC. | $18.71 | 2025 | Qutenza |
| Inspire Medical Systems, INC. | $17.55 | 2025 | Inspire |
| Echosens North America, INC. | $16.52 | 2025 | Fibroscan |
| Antares Pharma, INC. | $15.03 | 2024 | Xyosted |
| Madrigal Pharmaceuticals | $14.40 | 2025 | Rezdiffra |
| Azurity Pharmaceuticals, INC. | $14.09 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.